In June, pharmaceutical company ViiV Healthcare is expected to debut one of the world’s newest antiretrovirals (ARV), dolutegravir, in South Africa’s private sector for about R720 per month excluding VAT and dispensing fees.
In a 2012 study conducted among about 830 people, a dolutegravir-based combination that included the ARVs abacavir and lamivudine beat South Africa’s current three-in-one combination ARV in effectiveness and tolerability. Patients on the dolutegravir-based combination treatment also had a lower incidence of side effects like psychiatric, skin and gastrointestinal disorders.
According to ViiV Healthcare Global Medical Director, Jan van Lunzen, the drug’s long-release formulation also helps protect patients against the development of drug resistance.
Patients who had skipped several one or two doses would retain concentrations of the drug in their blood high enough to control the virus even 72 hours after they missed their medication, Van Lunzen told Health-e News.
Speaking at the Southern African HIV Clinicians Society conference late last week, Van Lunzen added that the drug can be taken with or without food – this is just one reason why the drug might be ideal for South Africa’s public sector.
Two-year delay in drug expected for public sector
However, Van Lunzen said he expects it will be at least two years before generic dolutegravir formulations will be registered with South African drug regulator, the Medicines Control Council.
The Treatment Action Campaign (TAC) is expected to call for the Medicine Control Council to fast-track approval of these producers.
A doctor who has seen the benefits of dolutegravir in his own patients, Van Lunzen said ViiV Healthcare is keen to see generic production ramped following a 2014 licensing agreement with the United Nations-backed organisation the Medicines Patent Pool.
Under the agreement, ViiV Healthcare would grant royalty-free, voluntary licenses to generic manufacturers to produce adult and paediatric formulation of dolutegravir for at least 67 countries, including South Africa.
Voluntary licenses no guarantee of generic production
The agreement is not unlike the deal signed between the pool and pharmaceutical company AbbVie in December that allowed generic manufacturers to produce its combination ARV Aluvia for countries including South Africa.
The agreement followed months of Aluvia shortages in South Africa due to AbbVie’s alleged inability to keep pace with South Africa’s demand. AbbVie’s patents prevented other companies from selling the drug in South Africa.
But AbbVie’s agreement with the pool may be a reminder that licenses are only one hurdle in the road to generic and even local manufacture of drugs and ultimately to making sure drugs end up in patient hands.
Susan Tafeni is the project manager for the Stop Stock Outs Project, a joint civil society medicine monitoring initiative comprised of organisations such as Médecins Sans Frontières and TAC.
Preliminary results of the project’s latest stock out survey conducted among about 60 percent of the country’s health facilities betrays the impact of the country’s over-reliance on a single supplier for Aluvia. According to the survey’s preliminary results, about one in four facilities reported an ARV or tuberculosis medication stock out. In about a quarter of cases, patients were sent home with either incomplete medication or none at all, according to Tafeni.
Aluvia accounted for about 40 percent of all ARV stock outs uncovered by the project. Shortages of Aluvia, which contains the ARVs lopinavir and ritonavir, fuelled a shortage of the ARV abacavir as clinicians scrambled to replace Aluvia in patients’ regimens.
Meanwhile, no local manufacturers have been able to begin producing the Aluvia allegedly due to the patent pool agreement’s limitations and their inability to undercut AbbVie’s already low prices, Tafeni added.
National Department of Health’s Chief Director of Sector Wide Procurement Gavin Steel has called the report a “post mortem,” saying that many of the problems identified in the report have been solved.
He added that the country has also achieved a 95 percent availability rate for its three-in-one ARV, which comprises treatment for the majority of South Africans on HIV treatment. – Health-e News.
An edited version of this story was also published in the Daily Maverick.
- Never miss a story. Subscribe to our free, weekly email newsletter
- Read more: Quarter of surveyed facilities report medicine stock outs in last year
But currently, the HIV medication is around R500 in total price, why should people pay more when they can hardly afford the R500 one-month medication?